An American scientist has developed a new capsule that can reduce the number of hospitalizations caused by the Kovid virus by half.
Named Molnupiravir, it was administered to Kovid patients in two capsules a day.
The company said the results were “extremely successful” and that the product had already been applied for emergency use.
In a study of 775 people, only 7.3% had symptoms that led to hospitalization.
No deaths were reported.
Several companies including Pfizer have already started producing coils but have not yet achieved any successful results.